SIMILAR PATTERNS OF AMINO ACIDS FOR 3EBZ_B_017B201_2

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1cb8	PROTEIN (CHONDROITINASE AC) (Pedobacter heparinus)	PF02278 (Lyase_8) PF02884 (Lyase_8_C) PF08124 (Lyase_8_N)	5	LEU A 296 GLY A 287 VAL A 237 GLY A 235 ILE A 231	None GOL A2010 ( 4.3A) None None None	1.08A	3ebzB-1cb8A: undetectable	3ebzB-1cb8A: 10.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1cyi	CYTOCHROME C6 (Chlamydomonas reinhardtii)	PF13442 (Cytochrome_CBB3)	5	LEU A 67 GLY A 6 ALA A 74 ASP A 2 ILE A 49	None None None None HEM A 200 ( 4.3A)	1.09A	3ebzB-1cyiA: undetectable	3ebzB-1cyiA: 14.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1dqw	OROTIDINE 5'-PHOSPHATE DECARBOXYLASE (Saccharomyces cerevisiae)	PF00215 (OMPdecase)	5	LEU A 51 GLY A 236 VAL A 220 ILE A 232 ILE A 55	None	1.02A	3ebzB-1dqwA: undetectable	3ebzB-1dqwA: 19.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1efv	ELECTRON TRANSFER FLAVOPROTEIN (Homo sapiens)	PF00766 (ETF_alpha) PF01012 (ETF)	5	GLY A 289 ALA A 288 ILE A 284 GLY A 282 ILE A 280	None None None None FAD A 599 (-4.3A)	1.05A	3ebzB-1efvA: undetectable	3ebzB-1efvA: 15.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1f3l	PROTEIN ARGININE METHYLTRANSFERASE PRMT3 (Rattus norvegicus)	PF06325 (PrmA)	5	LEU A 266 ASP A 258 ALA A 280 ILE A 286 ILE A 265	SAH A 529 ( 4.4A) SAH A 529 ( 4.4A) None None SAH A 529 (-4.9A)	0.95A	3ebzB-1f3lA: undetectable	3ebzB-1f3lA: 14.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h2b	ALCOHOL DEHYDROGENASE (Aeropyrum pernix)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	LEU A 226 GLY A 231 ALA A 232 ASP A 233 VAL A 190	None	1.10A	3ebzB-1h2bA: undetectable	3ebzB-1h2bA: 15.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1hkg	HEXOKINASE A (Saccharomyces cerevisiae)	PF00349 (Hexokinase_1) PF03727 (Hexokinase_2)	5	ASP A 431 GLY A 432 ALA A 435 ILE A 79 ILE A 67	None	1.07A	3ebzB-1hkgA: undetectable	3ebzB-1hkgA: 12.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A)	1.24A	3ebzB-1hvcA: 12.5	3ebzB-1hvcA: 27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A)	1.25A	3ebzB-1hvcA: 12.5	3ebzB-1hvcA: 27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.9A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A)	0.43A	3ebzB-1hvcA: 12.5	3ebzB-1hvcA: 27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A)	0.46A	3ebzB-1hvcA: 12.5	3ebzB-1hvcA: 27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1icp	12-OXOPHYTODIENOATE REDUCTASE 1 (Solanum lycopersicum)	PF00724 (Oxidored_FMN)	5	LEU A 293 GLY A 308 ALA A 307 ILE A 305 VAL A 32	None FMN A 501 (-3.5A) FMN A 501 ( 4.1A) None None	1.14A	3ebzB-1icpA: undetectable	3ebzB-1icpA: 15.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1jcf	ROD SHAPE-DETERMINING PROTEIN MREB (Thermotoga maritima)	PF06723 (MreB_Mbl)	5	LEU A 332 ASP A 108 GLY A 105 ILE A 104 ILE A 129	None	1.12A	3ebzB-1jcfA: undetectable	3ebzB-1jcfA: 17.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	5	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30	None	0.54A	3ebzB-1q9pA: 9.6	3ebzB-1q9pA: 49.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1rp0	THIAZOLE BIOSYNTHETIC ENZYME (Arabidopsis thaliana)	PF01946 (Thi4)	5	GLY A 194 ALA A 195 ILE A 246 VAL A 238 GLY A 240	None None None None AHZ A 600 (-3.5A)	0.72A	3ebzB-1rp0A: undetectable	3ebzB-1rp0A: 17.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	3ebzB-1sivA: 20.8	3ebzB-1sivA: 86.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 32 VAL A 47 ILE A 50	None	0.45A	3ebzB-1sivA: 20.8	3ebzB-1sivA: 86.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 47 GLY A 49 ILE A 50 ILE A 82	None	0.57A	3ebzB-1sivA: 20.8	3ebzB-1sivA: 86.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1xjl	ANNEXIN A2 (Homo sapiens)	PF00191 (Annexin)	5	GLY A 202 ALA A 201 ASP A 200 ASP A 197 ILE A 216	CA A 343 (-4.6A) None None None None	1.10A	3ebzB-1xjlA: undetectable	3ebzB-1xjlA: 14.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2abq	FRUCTOSE 1-PHOSPHATE KINASE (Bacillus halodurans)	PF00294 (PfkB)	5	ALA A 253 ILE A 2 VAL A 130 GLY A 39 ILE A 40	None	1.08A	3ebzB-2abqA: undetectable	3ebzB-2abqA: 15.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dws	COPPER-CONTAINING NITRITE REDUCTASE (Rhodobacter sphaeroides)	PF00394 (Cu-oxidase) PF07732 (Cu-oxidase_3)	5	GLY A 254 ALA A 255 GLY A 347 ILE A 250 ILE A 217	None	0.81A	3ebzB-2dwsA: undetectable	3ebzB-2dwsA: 18.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	6	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 55	None LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) LP1 A 201 (-3.4A)	0.26A	3ebzB-2fmbA: 15.5	3ebzB-2fmbA: 37.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2g3a	ACETYLTRANSFERASE (Agrobacterium fabrum)	PF13673 (Acetyltransf_10)	5	GLY A 96 ALA A 97 ILE A 99 GLY A 114 ILE A 118	None	1.02A	3ebzB-2g3aA: undetectable	3ebzB-2g3aA: 20.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hoq	PUTATIVE HAD-HYDROLASE PH1655 (Pyrococcus horikoshii)	PF13419 (HAD_2)	5	ALA A 162 VAL A 4 GLY A 114 ILE A 115 ILE A 155	None	0.97A	3ebzB-2hoqA: undetectable	3ebzB-2hoqA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2i39	PROTEIN N1 (Vaccinia virus)	PF06227 (Poxvirus)	5	LEU A 30 ASP A 35 ASP A 38 ILE A 75 ILE A 73	None	1.14A	3ebzB-2i39A: undetectable	3ebzB-2i39A: 21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2oby	PUTATIVE QUINONE OXIDOREDUCTASE (Homo sapiens)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	LEU A 145 GLY A 189 ALA A 188 ILE A 167 GLY A 185	None	0.90A	3ebzB-2obyA: undetectable	3ebzB-2obyA: 13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pl1	TRANSCRIPTIONAL REGULATORY PROTEIN PHOP (Escherichia coli)	PF00072 (Response_reg)	5	ALA A 36 ASP A 32 GLY A 59 ILE A 63 ILE A 49	None	1.04A	3ebzB-2pl1A: undetectable	3ebzB-2pl1A: 21.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rkf	PROTEASE RETROPEPSIN (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 32 VAL A 47 GLY A 49 ILE A 50	None AB1 A 501 (-2.4A) AB1 A 501 (-3.9A) AB1 A 501 (-3.5A) AB1 A 501 ( 3.3A) AB1 A 501 (-3.8A) AB1 A 501 (-4.5A) AB1 A 501 ( 4.9A) AB1 A 501 (-3.5A) AB1 A 501 (-3.8A)	0.52A	3ebzB-2rkfA: 18.9	3ebzB-2rkfA: 49.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2rsp	RSV PROTEASE (Rous sarcoma virus)	PF00077 (RVP)	6	LEU A 35 ASP A 37 GLY A 39 ALA A 40 ASP A 41 ILE A 44	None	0.42A	3ebzB-2rspA: 12.8	3ebzB-2rspA: 29.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y9e	MYOSIN-2 (Dictyostelium discoideum)	PF00063 (Myosin_head) PF02736 (Myosin_N)	5	GLY X 255 ALA X 256 ILE X 258 GLY X 451 ILE X 450	None	1.12A	3ebzB-2y9eX: undetectable	3ebzB-2y9eX: 8.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zpa	UNCHARACTERIZED PROTEIN YPFI (Escherichia coli)	PF05127 (Helicase_RecD) PF08351 (DUF1726) PF13718 (GNAT_acetyltr_2) PF17176 (tRNA_bind_3)	5	GLY A 375 ALA A 376 ILE A 461 GLY A 407 ILE A 405	None ACO A 700 ( 4.5A) ACO A 700 (-4.1A) None None	1.06A	3ebzB-2zpaA: undetectable	3ebzB-2zpaA: 9.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c5w	PP2A A SUBUNIT (Homo sapiens)	PF02985 (HEAT) PF13646 (HEAT_2)	5	LEU A 567 ALA A 582 GLY A 548 ILE A 547 ILE A 563	None	0.83A	3ebzB-3c5wA: undetectable	3ebzB-3c5wA: 18.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3cpf	EUKARYOTIC TRANSLATION INITIATION FACTOR 5A-1 (Homo sapiens)	PF01287 (eIF-5a)	5	GLY A 130 ASP A 128 ILE A 123 GLY A 93 ILE A 92	UNX A 4 ( 3.7A) None None None None	1.05A	3ebzB-3cpfA: undetectable	3ebzB-3cpfA: 25.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ctk	RRNA N-GLYCOSIDASE (Bougainvillea spectabilis)	PF00161 (RIP)	5	LEU A 157 GLY A 112 ILE A 152 VAL A 85 GLY A 73	None	1.04A	3ebzB-3ctkA: undetectable	3ebzB-3ctkA: 17.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7l	LIN1944 PROTEIN (Listeria innocua)	PF13561 (adh_short_C2)	5	GLY A 30 ALA A 29 ASP A 35 ILE A 27 ILE A 59	None	1.10A	3ebzB-3d7lA: undetectable	3ebzB-3d7lA: 22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lup	DEGV FAMILY PROTEIN (Streptococcus agalactiae)	PF02645 (DegV)	5	ALA A 230 ILE A 278 VAL A 218 ILE A 159 ILE A 119	None	0.97A	3ebzB-3lupA: undetectable	3ebzB-3lupA: 18.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.27A	3ebzB-3mwsA: 19.4	3ebzB-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30	None	0.48A	3ebzB-3mwsA: 19.4	3ebzB-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.27A	3ebzB-3mwsA: 19.4	3ebzB-3mwsA: 48.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nwg	MICROCOMPARTMENTS PROTEIN (Desulfitobacterium hafniense)	PF00936 (BMC)	5	GLY A 153 ALA A 114 GLY A 97 ILE A 98 ILE A 125	None	1.04A	3ebzB-3nwgA: undetectable	3ebzB-3nwgA: 21.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3oqb	OXIDOREDUCTASE (Bradyrhizobium diazoefficiens)	PF01408 (GFO_IDH_MocA)	5	LEU A 24 GLY A 13 ALA A 90 ILE A 10 ILE A 28	None	1.10A	3ebzB-3oqbA: undetectable	3ebzB-3oqbA: 14.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3p4g	ANTIFREEZE PROTEIN (Marinomonas primoryensis)	no annotation	5	ASP A 122 GLY A 118 ALA A 117 ILE A 143 GLY A 156	CA A 404 ( 2.4A) CA A 404 (-4.1A) CA A 405 (-4.7A) None CA A 406 (-4.0A)	0.98A	3ebzB-3p4gA: undetectable	3ebzB-3p4gA: 18.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	6	LEU A 30 ASP A 32 GLY A 34 ALA A 35 VAL A 54 GLY A 56	None 3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) 3TL A 126 (-3.3A) 3TL A 126 (-3.4A)	0.37A	3ebzB-3slzA: 12.2	3ebzB-3slzA: 25.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) 017 A 201 (-4.0A) 017 A 201 (-3.3A)	1.22A	3ebzB-3t3cA: 19.1	3ebzB-3t3cA: 50.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) 017 A 201 (-4.0A) 017 A 201 (-3.3A)	0.22A	3ebzB-3t3cA: 19.1	3ebzB-3t3cA: 50.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3t9n	SMALL-CONDUCTANCE MECHANOSENSITIVE CHANNEL (Caldanaerobacter subterraneus)	PF00924 (MS_channel)	5	GLY A 81 ALA A 80 ILE A 30 ILE A 75 ILE A 35	None	1.09A	3ebzB-3t9nA: undetectable	3ebzB-3t9nA: 16.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None 017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-3.0A) 017 A 201 (-3.3A)	1.24A	3ebzB-3ttpA: 19.7	3ebzB-3ttpA: 52.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 50	None 017 A 201 (-2.6A) 017 A 201 (-3.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-4.6A) 017 A 201 (-3.3A)	0.39A	3ebzB-3ttpA: 19.7	3ebzB-3ttpA: 52.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 32 VAL A 47 GLY A 49 ILE A 50	None 017 A 201 (-2.6A) 017 A 201 (-3.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) None 017 A 201 ( 4.9A) 017 A 201 (-3.0A) 017 A 201 (-3.3A)	0.47A	3ebzB-3ttpA: 19.7	3ebzB-3ttpA: 52.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	None 017 A 202 ( 2.5A) 017 A 201 (-3.4A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A)	1.27A	3ebzB-3u7sA: 19.3	3ebzB-3u7sA: 47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 32 GLY A 49 ILE A 50	None 017 A 202 ( 2.5A) 017 A 201 ( 3.5A) 017 A 201 (-3.4A) 017 A 201 (-3.2A) 017 A 201 ( 4.0A) None 017 A 202 (-2.9A) 017 A 201 ( 3.5A)	0.39A	3ebzB-3u7sA: 19.3	3ebzB-3u7sA: 47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3uhl	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 32	None	0.35A	3ebzB-3uhlA: 16.6	3ebzB-3uhlA: 49.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wxm	PROTEIN PELOTA HOMOLOG (Aeropyrum pernix)	PF03463 (eRF1_1) PF03465 (eRF1_3)	5	GLY B 198 ALA B 197 ILE B 131 VAL B 241 ILE B 182	None	1.14A	3ebzB-3wxmB: undetectable	3ebzB-3wxmB: 14.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4d61	EUKARYOTIC PEPTIDE CHAIN RELEASE FACTOR GTP-BINDING SUBUNIT ERF3A (Homo sapiens)	PF01201 (Ribosomal_S8e)	5	LEU i 586 GLY i 618 VAL i 561 ILE i 528 ILE i 554	None	0.94A	3ebzB-4d61i: undetectable	3ebzB-4d61i: 13.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4dzt	AQUALYSIN-1 (Thermus aquaticus)	PF00082 (Peptidase_S8)	5	GLY A 103 ASP A 39 ILE A 38 GLY A 130 ILE A 109	None	1.14A	3ebzB-4dztA: undetectable	3ebzB-4dztA: 14.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fgs	PROBABLE DEHYDROGENASE PROTEIN (Rhizobium etli)	PF13561 (adh_short_C2)	5	GLY A 14 ALA A 15 ILE A 51 VAL A 34 ILE A 58	None	1.03A	3ebzB-4fgsA: undetectable	3ebzB-4fgsA: 16.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ida	RIPENING-INDUCED PROTEIN (Fragaria vesca)	PF08240 (ADH_N) PF13602 (ADH_zinc_N_2)	5	LEU A 203 GLY A 208 ALA A 209 ASP A 210 ILE A 179	None	0.82A	3ebzB-4idaA: undetectable	3ebzB-4idaA: 16.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4j2h	SHORT CHAIN ALCOHOL DEHYDROGENASE-RELATE D DEHYDROGENASE (Sinorhizobium meliloti)	PF13561 (adh_short_C2)	5	ASP A 248 GLY A 249 ASP A 224 ILE A 187 VAL A 228	None	0.99A	3ebzB-4j2hA: undetectable	3ebzB-4j2hA: 19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jd0	NUCLEOTIDYL TRANSFERASE (Thermotoga maritima)	PF00483 (NTP_transferase)	5	LEU A 7 ALA A 4 VAL A 71 GLY A 73 ILE A 74	GOL A 314 (-4.7A) None None None None	0.79A	3ebzB-4jd0A: undetectable	3ebzB-4jd0A: 23.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lac	PP2A SCAFFOLD SUBUNIT A, TRUNCATED, AN INTERNAL DELETION OF PP2A A (Homo sapiens)	PF02985 (HEAT) PF13646 (HEAT_2)	5	LEU A 567 ALA A 582 GLY A 548 ILE A 547 ILE A 563	None	0.75A	3ebzB-4lacA: undetectable	3ebzB-4lacA: 18.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mn6	SENSOR PROTEIN KINASE WALK (Staphylococcus aureus)	PF13426 (PAS_9)	5	GLY A 275 ALA A 292 ILE A 303 VAL A 311 ILE A 287	None	0.91A	3ebzB-4mn6A: undetectable	3ebzB-4mn6A: 20.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None RIT A 500 (-2.4A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-3.4A) RIT A 500 (-4.3A)	1.29A	3ebzB-4njvA: 18.6	3ebzB-4njvA: 47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A)	0.47A	3ebzB-4njvA: 18.6	3ebzB-4njvA: 47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-3.4A) RIT A 500 (-4.3A)	0.39A	3ebzB-4njvA: 18.6	3ebzB-4njvA: 47.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4olq	ENOYL-COA HYDRATASE/ISOMERASE FAMILY PROTEIN (Hyphomonas neptunium)	PF00378 (ECH_1)	5	GLY A 59 ALA A 58 ASP A 57 VAL A 17 ILE A 105	None	1.15A	3ebzB-4olqA: undetectable	3ebzB-4olqA: 18.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4p7y	METHIONINE GAMMA-LYASE (Citrobacter freundii)	PF01053 (Cys_Met_Meta_PP)	5	GLY A 244 ILE A 222 VAL A 208 GLY A 88 ILE A 89	None None None LLP A 210 ( 3.5A) LLP A 210 ( 4.3A)	1.04A	3ebzB-4p7yA: undetectable	3ebzB-4p7yA: 14.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rgh	PROTEIN DDI1 HOMOLOG 2 (Homo sapiens)	PF09668 (Asp_protease)	5	ASP A 220 GLY A 222 ALA A 223 ILE A 227 GLY A 252	None	0.90A	3ebzB-4rghA: 10.9	3ebzB-4rghA: 18.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4to8	FRUCTOSE-1,6-BISPHOS PHATE ALDOLASE, CLASS II (Staphylococcus aureus)	PF01116 (F_bP_aldolase)	5	GLY A 274 ILE A 34 VAL A 45 GLY A 21 ILE A 230	None	0.83A	3ebzB-4to8A: undetectable	3ebzB-4to8A: 16.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wzw	PUMILIO DOMAIN-CONTAINING PROTEIN KIAA0020 (Homo sapiens)	PF08144 (CPL)	5	LEU A 606 GLY A 599 GLY A 554 ILE A 548 ILE A 562	None	1.09A	3ebzB-4wzwA: undetectable	3ebzB-4wzwA: 14.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xeh	KETOL-ACID REDUCTOISOMERASE (Ignisphaera aggregans)	PF01450 (IlvC) PF07991 (IlvN)	5	LEU A 166 ALA A 149 ILE A 172 VAL A 137 GLY A 146	None	0.86A	3ebzB-4xehA: undetectable	3ebzB-4xehA: 16.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	7	LEU A 30 ASP A 32 GLY A 34 ALA A 35 ASP A 36 VAL A 56 GLY A 58	None 4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) None 4B1 A 201 (-3.4A)	0.42A	3ebzB-4ydfA: 12.7	3ebzB-4ydfA: 35.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ywk	CELL DIVISION CONTROL PROTEIN 21 (Pyrococcus furiosus)	PF14551 (MCM_N) PF17207 (MCM_OB)	5	ASP A 106 ILE A 203 VAL A 118 GLY A 120 ILE A 121	None	0.82A	3ebzB-4ywkA: undetectable	3ebzB-4ywkA: 20.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ywl	CELL DIVISION CONTROL PROTEIN 21 (Pyrococcus furiosus)	PF14551 (MCM_N) PF17207 (MCM_OB)	5	ASP A 106 ILE A 203 VAL A 118 GLY A 120 ILE A 121	None	0.95A	3ebzB-4ywlA: undetectable	3ebzB-4ywlA: 17.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4zdl	O-PHOSPHOSERYL-TRNA( SEC) SELENIUM TRANSFERASE (Homo sapiens)	PF05889 (SepSecS)	5	ASP A 62 GLY A 110 GLY A 96 ILE A 95 ILE A 92	None	0.85A	3ebzB-4zdlA: undetectable	3ebzB-4zdlA: 14.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 32	None	0.48A	3ebzB-5b18A: 18.5	3ebzB-5b18A: 47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 47 GLY A 49	None	0.86A	3ebzB-5b18A: 18.5	3ebzB-5b18A: 47.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5cwa	ANTHRANILATE SYNTHASE COMPONENT 1 (Mycobacterium tuberculosis)	PF00425 (Chorismate_bind) PF04715 (Anth_synt_I_N)	5	LEU A 125 ASP A 447 GLY A 450 ALA A 449 ASP A 115	None	1.06A	3ebzB-5cwaA: undetectable	3ebzB-5cwaA: 12.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5d7a	TRAF2 AND NCK-INTERACTING PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 138 GLY A 220 ALA A 223 ILE A 133 GLY A 156	LEU A 138 ( 0.6A) GLY A 220 ( 0.0A) ALA A 223 ( 0.0A) ILE A 133 ( 0.6A) GLY A 156 ( 0.0A)	1.07A	3ebzB-5d7aA: undetectable	3ebzB-5d7aA: 16.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5doo	PROTEIN LYSINE METHYLTRANSFERASE 2 (Rickettsia typhi)	PF10119 (MethyTransf_Reg) PF13847 (Methyltransf_31)	5	LEU A 75 ASP A 74 ASP A 49 ILE A 50 GLY A 119	None	1.13A	3ebzB-5dooA: undetectable	3ebzB-5dooA: 11.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e4r	KETOL-ACID REDUCTOISOMERASE (Ignisphaera aggregans)	PF01450 (IlvC) PF07991 (IlvN)	5	LEU A 166 ALA A 149 ILE A 172 VAL A 137 GLY A 146	None	0.87A	3ebzB-5e4rA: undetectable	3ebzB-5e4rA: 12.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iuw	ALDEHYDE DEHYDROGENASE FAMILY PROTEIN (Pseudomonas syringae group genomosp. 3)	no annotation	5	GLY A 364 ALA A 365 ASP A 389 VAL A 409 ILE A 357	None	1.14A	3ebzB-5iuwA: undetectable	3ebzB-5iuwA: 12.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jys	PROTEIN PRY1 (Saccharomyces cerevisiae)	PF00188 (CAP)	5	LEU A 217 ALA A 226 ASP A 222 ILE A 266 ILE A 278	MG A 301 (-3.9A) None None None None	1.15A	3ebzB-5jysA: undetectable	3ebzB-5jysA: 14.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ldn	HEXON PROTEIN,HEXON CAPSID (Human mastadenovirus C)	PF01065 (Adeno_hexon) PF03678 (Adeno_hexon_C)	5	GLY A 220 ALA A 171 ILE A 215 GLY A 206 ILE A 205	None	0.81A	3ebzB-5ldnA: undetectable	3ebzB-5ldnA: 9.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5mpd	26S PROTEASOME REGULATORY SUBUNIT RPN2 (Saccharomyces cerevisiae)	PF01851 (PC_rep) PF13646 (HEAT_2)	5	GLY N 698 ALA N 699 GLY N 704 ILE N 705 ILE N 678	None	0.78A	3ebzB-5mpdN: undetectable	3ebzB-5mpdN: 7.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5n7f	MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAIN-CONTAINING PROTEIN 1,ANNEXIN A2 (Homo sapiens)	no annotation	5	GLY A 741 ALA A 740 ASP A 739 ASP A 736 ILE A 755	CA A 905 (-4.7A) None None None None	1.03A	3ebzB-5n7fA: undetectable	3ebzB-5n7fA: 13.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5nd1	CAPSID PROTEIN (Rosellinia necatrix quadrivirus 1)	no annotation	5	GLY B 438 ALA B 581 ASP A 872 VAL A 870 ILE B 689	None	1.09A	3ebzB-5nd1B: undetectable	3ebzB-5nd1B: 19.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.27A	3ebzB-5t2zA: 19.2	3ebzB-5t2zA: 49.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	None	0.41A	3ebzB-5t2zA: 19.2	3ebzB-5t2zA: 49.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x1n	VANILLATE/3-O-METHYL GALLATE O-DEMETHYLASE (Sphingobium sp. SYK-6)	PF01571 (GCV_T) PF08669 (GCV_T_C)	5	GLY A 168 ALA A 171 ASP A 173 GLY A 238 ILE A 230	None	1.14A	3ebzB-5x1nA: undetectable	3ebzB-5x1nA: 16.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	5	LEU A 308 ASP A 305 GLY A 272 GLY A 165 ILE A 152	None	1.01A	3ebzB-5xd6A: undetectable	3ebzB-5xd6A: 22.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5yeq	KETOL-ACID REDUCTOISOMERASE (NADP(+)) (Sulfolobus acidocaldarius)	no annotation	5	LEU A 166 ALA A 149 ILE A 172 VAL A 137 GLY A 146	None	0.87A	3ebzB-5yeqA: undetectable	3ebzB-5yeqA: 19.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cc2	CELL DIVISION CONTROL PROTEIN 45 CDC45 PUTATIVE (Entamoeba histolytica)	no annotation	5	GLY A 396 ALA A 360 ILE A 206 VAL A 33 GLY A 381	None	0.97A	3ebzB-6cc2A: undetectable	3ebzB-6cc2A: 18.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dus	TYPE III SECRETION SYSTEM EFFECTOR PROTEIN (Salmonella enterica)	no annotation	5	LEU A 76 ALA A 227 ASP A 226 ASP A 228 ILE A 80	MPD A 506 ( 4.9A) UDP A 501 (-3.8A) UDP A 501 (-3.4A) MG A 503 ( 2.4A) MPD A 506 (-4.5A)	1.14A	3ebzB-6dusA: undetectable	3ebzB-6dusA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	7	LEU A 28 ASP A 30 GLY A 32 ALA A 33 ASP A 34 ILE A 37 GLY A 58	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) 3TL A 201 ( 4.8A) 3TL A 201 (-3.4A)	0.45A	3ebzB-6fivA: 15.8	3ebzB-6fivA: 31.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 82	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) NIU A 100 (-4.6A)	0.69A	3ebzB-6upjA: 19.0	3ebzB-6upjA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 32 GLY A 49	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A)	0.70A	3ebzB-6upjA: 19.0	3ebzB-6upjA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 32 VAL A 47 GLY A 49	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A)	0.66A	3ebzB-6upjA: 19.0	3ebzB-6upjA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ASP A 29 ASP A 30 GLY A 49 ILE A 50 ILE A 82	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) NIU A 100 (-4.6A)	0.80A	3ebzB-6upjA: 19.0	3ebzB-6upjA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ASP A 29 ILE A 32 GLY A 49 ILE A 50	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A)	0.81A	3ebzB-6upjA: 19.0	3ebzB-6upjA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ILE A 32 VAL A 47 GLY A 49 ILE A 50	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A)	0.77A	3ebzB-6upjA: 19.0	3ebzB-6upjA: 98.99

[["3EBZ_B_017B201_2","1cb8","Pedobacter heparinus","PROTEIN (CHONDROITINASE AC)","PF02278(Lyase_8);PF02884(Lyase_8_C);PF08124(Lyase_8_N)",5,"LEU A 296;GLY A 287;VAL A 237;GLY A 235;ILE A 231","None;GOL A2010 ( 4.3A);None;None;None","1.08A","3ebzB-1cb8A:undetectable","3ebzB-1cb8A:10.32"],["3EBZ_B_017B201_2","1cyi","Chlamydomonas reinhardtii","CYTOCHROME C6","PF13442(Cytochrome_CBB3)",5,"LEU A  67;GLY A   6;ALA A  74;ASP A   2;ILE A  49","None;None;None;None;HEM A 200 ( 4.3A)","1.09A","3ebzB-1cyiA:undetectable","3ebzB-1cyiA:14.71"],["3EBZ_B_017B201_2","1dqw","Saccharomyces cerevisiae","OROTIDINE 5'-PHOSPHATE DECARBOXYLASE","PF00215(OMPdecase)",5,"LEU A  51;GLY A 236;VAL A 220;ILE A 232;ILE A  55","None","1.02A","3ebzB-1dqwA:undetectable","3ebzB-1dqwA:19.01"],["3EBZ_B_017B201_2","1efv","Homo sapiens","ELECTRON TRANSFER FLAVOPROTEIN","PF00766(ETF_alpha);PF01012(ETF)",5,"GLY A 289;ALA A 288;ILE A 284;GLY A 282;ILE A 280","None;None;None;None;FAD A 599 (-4.3A)","1.05A","3ebzB-1efvA:undetectable","3ebzB-1efvA:15.06"],["3EBZ_B_017B201_2","1f3l","Rattus norvegicus","PROTEIN ARGININE METHYLTRANSFERASE PRMT3","PF06325(PrmA)",5,"LEU A 266;ASP A 258;ALA A 280;ILE A 286;ILE A 265","SAH A 529 ( 4.4A);SAH A 529 ( 4.4A);None;None;SAH A 529 (-4.9A)","0.95A","3ebzB-1f3lA:undetectable","3ebzB-1f3lA:14.15"],["3EBZ_B_017B201_2","1h2b","Aeropyrum pernix","ALCOHOL DEHYDROGENASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"LEU A 226;GLY A 231;ALA A 232;ASP A 233;VAL A 190","None","1.10A","3ebzB-1h2bA:undetectable","3ebzB-1h2bA:15.97"],["3EBZ_B_017B201_2","1hkg","Saccharomyces cerevisiae","HEXOKINASE A","PF00349(Hexokinase_1);PF03727(Hexokinase_2)",5,"ASP A 431;GLY A 432;ALA A 435;ILE A  79;ILE A  67","None","1.07A","3ebzB-1hkgA:undetectable","3ebzB-1hkgA:12.53"],["3EBZ_B_017B201_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A)","1.24A","3ebzB-1hvcA:12.5","3ebzB-1hvcA:27.09"],["3EBZ_B_017B201_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A)","1.25A","3ebzB-1hvcA:12.5","3ebzB-1hvcA:27.09"],["3EBZ_B_017B201_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.9A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A)","0.43A","3ebzB-1hvcA:12.5","3ebzB-1hvcA:27.09"],["3EBZ_B_017B201_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A)","0.46A","3ebzB-1hvcA:12.5","3ebzB-1hvcA:27.09"],["3EBZ_B_017B201_2","1icp","Solanum lycopersicum","12-OXOPHYTODIENOATE REDUCTASE 1","PF00724(Oxidored_FMN)",5,"LEU A 293;GLY A 308;ALA A 307;ILE A 305;VAL A  32","None;FMN A 501 (-3.5A);FMN A 501 ( 4.1A);None;None","1.14A","3ebzB-1icpA:undetectable","3ebzB-1icpA:15.43"],["3EBZ_B_017B201_2","1jcf","Thermotoga maritima","ROD SHAPE-DETERMINING PROTEIN MREB","PF06723(MreB_Mbl)",5,"LEU A 332;ASP A 108;GLY A 105;ILE A 104;ILE A 129","None","1.12A","3ebzB-1jcfA:undetectable","3ebzB-1jcfA:17.02"],["3EBZ_B_017B201_2","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",5,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30","None","0.54A","3ebzB-1q9pA:9.6","3ebzB-1q9pA:49.47"],["3EBZ_B_017B201_2","1rp0","Arabidopsis thaliana","THIAZOLE BIOSYNTHETIC ENZYME","PF01946(Thi4)",5,"GLY A 194;ALA A 195;ILE A 246;VAL A 238;GLY A 240","None;None;None;None;AHZ A 600 (-3.5A)","0.72A","3ebzB-1rp0A:undetectable","3ebzB-1rp0A:17.25"],["3EBZ_B_017B201_2","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","3ebzB-1sivA:20.8","3ebzB-1sivA:86.87"],["3EBZ_B_017B201_2","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  32;VAL A  47;ILE A  50","None","0.45A","3ebzB-1sivA:20.8","3ebzB-1sivA:86.87"],["3EBZ_B_017B201_2","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  47;GLY A  49;ILE A  50;ILE A  82","None","0.57A","3ebzB-1sivA:20.8","3ebzB-1sivA:86.87"],["3EBZ_B_017B201_2","1xjl","Homo sapiens","ANNEXIN A2","PF00191(Annexin)",5,"GLY A 202;ALA A 201;ASP A 200;ASP A 197;ILE A 216"," CA A 343 (-4.6A);None;None;None;None","1.10A","3ebzB-1xjlA:undetectable","3ebzB-1xjlA:14.78"],["3EBZ_B_017B201_2","2abq","Bacillus halodurans","FRUCTOSE 1-PHOSPHATE KINASE","PF00294(PfkB)",5,"ALA A 253;ILE A   2;VAL A 130;GLY A  39;ILE A  40","None","1.08A","3ebzB-2abqA:undetectable","3ebzB-2abqA:15.49"],["3EBZ_B_017B201_2","2dws","Rhodobacter sphaeroides","COPPER-CONTAINING NITRITE REDUCTASE","PF00394(Cu-oxidase);PF07732(Cu-oxidase_3)",5,"GLY A 254;ALA A 255;GLY A 347;ILE A 250;ILE A 217","None","0.81A","3ebzB-2dwsA:undetectable","3ebzB-2dwsA:18.18"],["3EBZ_B_017B201_2","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  55","None;LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);LP1 A 201 (-3.4A)","0.26A","3ebzB-2fmbA:15.5","3ebzB-2fmbA:37.61"],["3EBZ_B_017B201_2","2g3a","Agrobacterium fabrum","ACETYLTRANSFERASE","PF13673(Acetyltransf_10)",5,"GLY A  96;ALA A  97;ILE A  99;GLY A 114;ILE A 118","None","1.02A","3ebzB-2g3aA:undetectable","3ebzB-2g3aA:20.67"],["3EBZ_B_017B201_2","2hoq","Pyrococcus horikoshii","PUTATIVE HAD-HYDROLASE PH1655","PF13419(HAD_2)",5,"ALA A 162;VAL A   4;GLY A 114;ILE A 115;ILE A 155","None","0.97A","3ebzB-2hoqA:undetectable","3ebzB-2hoqA:18.38"],["3EBZ_B_017B201_2","2i39","Vaccinia virus","PROTEIN N1","PF06227(Poxvirus)",5,"LEU A  30;ASP A  35;ASP A  38;ILE A  75;ILE A  73","None","1.14A","3ebzB-2i39A:undetectable","3ebzB-2i39A:21.31"],["3EBZ_B_017B201_2","2oby","Homo sapiens","PUTATIVE QUINONE OXIDOREDUCTASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"LEU A 145;GLY A 189;ALA A 188;ILE A 167;GLY A 185","None","0.90A","3ebzB-2obyA:undetectable","3ebzB-2obyA:13.04"],["3EBZ_B_017B201_2","2pl1","Escherichia coli","TRANSCRIPTIONAL REGULATORY PROTEIN PHOP","PF00072(Response_reg)",5,"ALA A  36;ASP A  32;GLY A  59;ILE A  63;ILE A  49","None","1.04A","3ebzB-2pl1A:undetectable","3ebzB-2pl1A:21.26"],["3EBZ_B_017B201_2","2rkf","Human immunodeficiency virus 1","PROTEASE RETROPEPSIN","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  32;VAL A  47;GLY A  49;ILE A  50","None;AB1 A 501 (-2.4A);AB1 A 501 (-3.9A);AB1 A 501 (-3.5A);AB1 A 501 ( 3.3A);AB1 A 501 (-3.8A);AB1 A 501 (-4.5A);AB1 A 501 ( 4.9A);AB1 A 501 (-3.5A);AB1 A 501 (-3.8A)","0.52A","3ebzB-2rkfA:18.9","3ebzB-2rkfA:49.49"],["3EBZ_B_017B201_2","2rsp","Rous sarcoma virus","RSV PROTEASE","PF00077(RVP)",6,"LEU A  35;ASP A  37;GLY A  39;ALA A  40;ASP A  41;ILE A  44","None","0.42A","3ebzB-2rspA:12.8","3ebzB-2rspA:29.13"],["3EBZ_B_017B201_2","2y9e","Dictyostelium discoideum","MYOSIN-2","PF00063(Myosin_head);PF02736(Myosin_N)",5,"GLY X 255;ALA X 256;ILE X 258;GLY X 451;ILE X 450","None","1.12A","3ebzB-2y9eX:undetectable","3ebzB-2y9eX:8.54"],["3EBZ_B_017B201_2","2zpa","Escherichia coli","UNCHARACTERIZED PROTEIN YPFI","PF05127(Helicase_RecD);PF08351(DUF1726);PF13718(GNAT_acetyltr_2);PF17176(tRNA_bind_3)",5,"GLY A 375;ALA A 376;ILE A 461;GLY A 407;ILE A 405","None;ACO A 700 ( 4.5A);ACO A 700 (-4.1A);None;None","1.06A","3ebzB-2zpaA:undetectable","3ebzB-2zpaA:9.86"],["3EBZ_B_017B201_2","3c5w","Homo sapiens","PP2A A SUBUNIT","PF02985(HEAT);PF13646(HEAT_2)",5,"LEU A 567;ALA A 582;GLY A 548;ILE A 547;ILE A 563","None","0.83A","3ebzB-3c5wA:undetectable","3ebzB-3c5wA:18.50"],["3EBZ_B_017B201_2","3cpf","Homo sapiens","EUKARYOTIC TRANSLATION INITIATION FACTOR 5A-1","PF01287(eIF-5a)",5,"GLY A 130;ASP A 128;ILE A 123;GLY A  93;ILE A  92","UNX A   4 ( 3.7A);None;None;None;None","1.05A","3ebzB-3cpfA:undetectable","3ebzB-3cpfA:25.38"],["3EBZ_B_017B201_2","3ctk","Bougainvillea spectabilis","RRNA N-GLYCOSIDASE","PF00161(RIP)",5,"LEU A 157;GLY A 112;ILE A 152;VAL A  85;GLY A  73","None","1.04A","3ebzB-3ctkA:undetectable","3ebzB-3ctkA:17.41"],["3EBZ_B_017B201_2","3d7l","Listeria innocua","LIN1944 PROTEIN","PF13561(adh_short_C2)",5,"GLY A  30;ALA A  29;ASP A  35;ILE A  27;ILE A  59","None","1.10A","3ebzB-3d7lA:undetectable","3ebzB-3d7lA:22.78"],["3EBZ_B_017B201_2","3lup","Streptococcus agalactiae","DEGV FAMILY PROTEIN","PF02645(DegV)",5,"ALA A 230;ILE A 278;VAL A 218;ILE A 159;ILE A 119","None","0.97A","3ebzB-3lupA:undetectable","3ebzB-3lupA:18.25"],["3EBZ_B_017B201_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.27A","3ebzB-3mwsA:19.4","3ebzB-3mwsA:48.48"],["3EBZ_B_017B201_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30","None","0.48A","3ebzB-3mwsA:19.4","3ebzB-3mwsA:48.48"],["3EBZ_B_017B201_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.27A","3ebzB-3mwsA:19.4","3ebzB-3mwsA:48.48"],["3EBZ_B_017B201_2","3nwg","Desulfitobacterium hafniense","MICROCOMPARTMENTS PROTEIN","PF00936(BMC)",5,"GLY A 153;ALA A 114;GLY A  97;ILE A  98;ILE A 125","None","1.04A","3ebzB-3nwgA:undetectable","3ebzB-3nwgA:21.98"],["3EBZ_B_017B201_2","3oqb","Bradyrhizobium diazoefficiens","OXIDOREDUCTASE","PF01408(GFO_IDH_MocA)",5,"LEU A  24;GLY A  13;ALA A  90;ILE A  10;ILE A  28","None","1.10A","3ebzB-3oqbA:undetectable","3ebzB-3oqbA:14.13"],["3EBZ_B_017B201_2","3p4g","Marinomonas primoryensis","ANTIFREEZE PROTEIN","no annotation",5,"ASP A 122;GLY A 118;ALA A 117;ILE A 143;GLY A 156"," CA A 404 ( 2.4A); CA A 404 (-4.1A); CA A 405 (-4.7A);None; CA A 406 (-4.0A)","0.98A","3ebzB-3p4gA:undetectable","3ebzB-3p4gA:18.12"],["3EBZ_B_017B201_2","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;VAL A  54;GLY A  56","None;3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);3TL A 126 (-3.3A);3TL A 126 (-3.4A)","0.37A","3ebzB-3slzA:12.2","3ebzB-3slzA:25.71"],["3EBZ_B_017B201_2","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.5A);017 A 201 (-4.2A);017 A 201 (-4.0A);017 A 201 (-3.3A)","1.22A","3ebzB-3t3cA:19.1","3ebzB-3t3cA:50.51"],["3EBZ_B_017B201_2","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.5A);017 A 201 (-3.5A);017 A 201 (-4.2A);017 A 201 (-4.0A);017 A 201 (-3.3A)","0.22A","3ebzB-3t3cA:19.1","3ebzB-3t3cA:50.51"],["3EBZ_B_017B201_2","3t9n","Caldanaerobacter subterraneus","SMALL-CONDUCTANCE MECHANOSENSITIVE CHANNEL","PF00924(MS_channel)",5,"GLY A  81;ALA A  80;ILE A  30;ILE A  75;ILE A  35","None","1.09A","3ebzB-3t9nA:undetectable","3ebzB-3t9nA:16.31"],["3EBZ_B_017B201_2","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None;017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-3.0A);017 A 201 (-3.3A)","1.24A","3ebzB-3ttpA:19.7","3ebzB-3ttpA:52.53"],["3EBZ_B_017B201_2","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  50","None;017 A 201 (-2.6A);017 A 201 (-3.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-4.6A);017 A 201 (-3.3A)","0.39A","3ebzB-3ttpA:19.7","3ebzB-3ttpA:52.53"],["3EBZ_B_017B201_2","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  32;VAL A  47;GLY A  49;ILE A  50","None;017 A 201 (-2.6A);017 A 201 (-3.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);None;017 A 201 ( 4.9A);017 A 201 (-3.0A);017 A 201 (-3.3A)","0.47A","3ebzB-3ttpA:19.7","3ebzB-3ttpA:52.53"],["3EBZ_B_017B201_2","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","None;017 A 202 ( 2.5A);017 A 201 (-3.4A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A)","1.27A","3ebzB-3u7sA:19.3","3ebzB-3u7sA:47.47"],["3EBZ_B_017B201_2","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  32;GLY A  49;ILE A  50","None;017 A 202 ( 2.5A);017 A 201 ( 3.5A);017 A 201 (-3.4A);017 A 201 (-3.2A);017 A 201 ( 4.0A);None;017 A 202 (-2.9A);017 A 201 ( 3.5A)","0.39A","3ebzB-3u7sA:19.3","3ebzB-3u7sA:47.47"],["3EBZ_B_017B201_2","3uhl","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  32","None","0.35A","3ebzB-3uhlA:16.6","3ebzB-3uhlA:49.49"],["3EBZ_B_017B201_2","3wxm","Aeropyrum pernix","PROTEIN PELOTA HOMOLOG","PF03463(eRF1_1);PF03465(eRF1_3)",5,"GLY B 198;ALA B 197;ILE B 131;VAL B 241;ILE B 182","None","1.14A","3ebzB-3wxmB:undetectable","3ebzB-3wxmB:14.52"],["3EBZ_B_017B201_2","4d61","Homo sapiens","EUKARYOTIC PEPTIDE CHAIN RELEASE FACTOR GTP-BINDING SUBUNIT ERF3A","PF01201(Ribosomal_S8e)",5,"LEU i 586;GLY i 618;VAL i 561;ILE i 528;ILE i 554","None","0.94A","3ebzB-4d61i:undetectable","3ebzB-4d61i:13.62"],["3EBZ_B_017B201_2","4dzt","Thermus aquaticus","AQUALYSIN-1","PF00082(Peptidase_S8)",5,"GLY A 103;ASP A  39;ILE A  38;GLY A 130;ILE A 109","None","1.14A","3ebzB-4dztA:undetectable","3ebzB-4dztA:14.75"],["3EBZ_B_017B201_2","4fgs","Rhizobium etli","PROBABLE DEHYDROGENASE PROTEIN","PF13561(adh_short_C2)",5,"GLY A  14;ALA A  15;ILE A  51;VAL A  34;ILE A  58","None","1.03A","3ebzB-4fgsA:undetectable","3ebzB-4fgsA:16.85"],["3EBZ_B_017B201_2","4ida","Fragaria vesca","RIPENING-INDUCED PROTEIN","PF08240(ADH_N);PF13602(ADH_zinc_N_2)",5,"LEU A 203;GLY A 208;ALA A 209;ASP A 210;ILE A 179","None","0.82A","3ebzB-4idaA:undetectable","3ebzB-4idaA:16.24"],["3EBZ_B_017B201_2","4j2h","Sinorhizobium meliloti","SHORT CHAIN ALCOHOL DEHYDROGENASE-RELATED DEHYDROGENASE","PF13561(adh_short_C2)",5,"ASP A 248;GLY A 249;ASP A 224;ILE A 187;VAL A 228","None","0.99A","3ebzB-4j2hA:undetectable","3ebzB-4j2hA:19.05"],["3EBZ_B_017B201_2","4jd0","Thermotoga maritima","NUCLEOTIDYL TRANSFERASE","PF00483(NTP_transferase)",5,"LEU A   7;ALA A   4;VAL A  71;GLY A  73;ILE A  74","GOL A 314 (-4.7A);None;None;None;None","0.79A","3ebzB-4jd0A:undetectable","3ebzB-4jd0A:23.15"],["3EBZ_B_017B201_2","4lac","Homo sapiens","PP2A SCAFFOLD SUBUNIT A, TRUNCATED, AN INTERNAL DELETION OF PP2A A","PF02985(HEAT);PF13646(HEAT_2)",5,"LEU A 567;ALA A 582;GLY A 548;ILE A 547;ILE A 563","None","0.75A","3ebzB-4lacA:undetectable","3ebzB-4lacA:18.06"],["3EBZ_B_017B201_2","4mn6","Staphylococcus aureus","SENSOR PROTEIN KINASE WALK","PF13426(PAS_9)",5,"GLY A 275;ALA A 292;ILE A 303;VAL A 311;ILE A 287","None","0.91A","3ebzB-4mn6A:undetectable","3ebzB-4mn6A:20.87"],["3EBZ_B_017B201_2","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None;RIT A 500 (-2.4A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-3.4A);RIT A 500 (-4.3A)","1.29A","3ebzB-4njvA:18.6","3ebzB-4njvA:47.47"],["3EBZ_B_017B201_2","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A)","0.47A","3ebzB-4njvA:18.6","3ebzB-4njvA:47.47"],["3EBZ_B_017B201_2","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-3.4A);RIT A 500 (-4.3A)","0.39A","3ebzB-4njvA:18.6","3ebzB-4njvA:47.47"],["3EBZ_B_017B201_2","4olq","Hyphomonas neptunium","ENOYL-COA HYDRATASE\/ISOMERASE FAMILY PROTEIN","PF00378(ECH_1)",5,"GLY A  59;ALA A  58;ASP A  57;VAL A  17;ILE A 105","None","1.15A","3ebzB-4olqA:undetectable","3ebzB-4olqA:18.25"],["3EBZ_B_017B201_2","4p7y","Citrobacter freundii","METHIONINE GAMMA-LYASE","PF01053(Cys_Met_Meta_PP)",5,"GLY A 244;ILE A 222;VAL A 208;GLY A  88;ILE A  89","None;None;None;LLP A 210 ( 3.5A);LLP A 210 ( 4.3A)","1.04A","3ebzB-4p7yA:undetectable","3ebzB-4p7yA:14.72"],["3EBZ_B_017B201_2","4rgh","Homo sapiens","PROTEIN DDI1 HOMOLOG 2","PF09668(Asp_protease)",5,"ASP A 220;GLY A 222;ALA A 223;ILE A 227;GLY A 252","None","0.90A","3ebzB-4rghA:10.9","3ebzB-4rghA:18.93"],["3EBZ_B_017B201_2","4to8","Staphylococcus aureus","FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE, CLASS II","PF01116(F_bP_aldolase)",5,"GLY A 274;ILE A  34;VAL A  45;GLY A  21;ILE A 230","None","0.83A","3ebzB-4to8A:undetectable","3ebzB-4to8A:16.10"],["3EBZ_B_017B201_2","4wzw","Homo sapiens","PUMILIO DOMAIN-CONTAINING PROTEIN KIAA0020","PF08144(CPL)",5,"LEU A 606;GLY A 599;GLY A 554;ILE A 548;ILE A 562","None","1.09A","3ebzB-4wzwA:undetectable","3ebzB-4wzwA:14.05"],["3EBZ_B_017B201_2","4xeh","Ignisphaera aggregans","KETOL-ACID REDUCTOISOMERASE","PF01450(IlvC);PF07991(IlvN)",5,"LEU A 166;ALA A 149;ILE A 172;VAL A 137;GLY A 146","None","0.86A","3ebzB-4xehA:undetectable","3ebzB-4xehA:16.37"],["3EBZ_B_017B201_2","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",7,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;ASP A  36;VAL A  56;GLY A  58","None;4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);None;4B1 A 201 (-3.4A)","0.42A","3ebzB-4ydfA:12.7","3ebzB-4ydfA:35.04"],["3EBZ_B_017B201_2","4ywk","Pyrococcus furiosus","CELL DIVISION CONTROL PROTEIN 21","PF14551(MCM_N);PF17207(MCM_OB)",5,"ASP A 106;ILE A 203;VAL A 118;GLY A 120;ILE A 121","None","0.82A","3ebzB-4ywkA:undetectable","3ebzB-4ywkA:20.10"],["3EBZ_B_017B201_2","4ywl","Pyrococcus furiosus","CELL DIVISION CONTROL PROTEIN 21","PF14551(MCM_N);PF17207(MCM_OB)",5,"ASP A 106;ILE A 203;VAL A 118;GLY A 120;ILE A 121","None","0.95A","3ebzB-4ywlA:undetectable","3ebzB-4ywlA:17.14"],["3EBZ_B_017B201_2","4zdl","Homo sapiens","O-PHOSPHOSERYL-TRNA(SEC) SELENIUM TRANSFERASE","PF05889(SepSecS)",5,"ASP A  62;GLY A 110;GLY A  96;ILE A  95;ILE A  92","None","0.85A","3ebzB-4zdlA:undetectable","3ebzB-4zdlA:14.03"],["3EBZ_B_017B201_2","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  32","None","0.48A","3ebzB-5b18A:18.5","3ebzB-5b18A:47.47"],["3EBZ_B_017B201_2","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  47;GLY A  49","None","0.86A","3ebzB-5b18A:18.5","3ebzB-5b18A:47.47"],["3EBZ_B_017B201_2","5cwa","Mycobacterium tuberculosis","ANTHRANILATE SYNTHASE COMPONENT 1","PF00425(Chorismate_bind);PF04715(Anth_synt_I_N)",5,"LEU A 125;ASP A 447;GLY A 450;ALA A 449;ASP A 115","None","1.06A","3ebzB-5cwaA:undetectable","3ebzB-5cwaA:12.60"],["3EBZ_B_017B201_2","5d7a","Homo sapiens","TRAF2 AND NCK-INTERACTING PROTEIN KINASE","PF00069(Pkinase)",5,"LEU A 138;GLY A 220;ALA A 223;ILE A 133;GLY A 156","LEU A 138 ( 0.6A);GLY A 220 ( 0.0A);ALA A 223 ( 0.0A);ILE A 133 ( 0.6A);GLY A 156 ( 0.0A)","1.07A","3ebzB-5d7aA:undetectable","3ebzB-5d7aA:16.78"],["3EBZ_B_017B201_2","5doo","Rickettsia typhi","PROTEIN LYSINE METHYLTRANSFERASE 2","PF10119(MethyTransf_Reg);PF13847(Methyltransf_31)",5,"LEU A  75;ASP A  74;ASP A  49;ILE A  50;GLY A 119","None","1.13A","3ebzB-5dooA:undetectable","3ebzB-5dooA:11.78"],["3EBZ_B_017B201_2","5e4r","Ignisphaera aggregans","KETOL-ACID REDUCTOISOMERASE","PF01450(IlvC);PF07991(IlvN)",5,"LEU A 166;ALA A 149;ILE A 172;VAL A 137;GLY A 146","None","0.87A","3ebzB-5e4rA:undetectable","3ebzB-5e4rA:12.84"],["3EBZ_B_017B201_2","5iuw","Pseudomonas syringae group genomosp. 3","ALDEHYDE DEHYDROGENASE FAMILY PROTEIN","no annotation",5,"GLY A 364;ALA A 365;ASP A 389;VAL A 409;ILE A 357","None","1.14A","3ebzB-5iuwA:undetectable","3ebzB-5iuwA:12.68"],["3EBZ_B_017B201_2","5jys","Saccharomyces cerevisiae","PROTEIN PRY1","PF00188(CAP)",5,"LEU A 217;ALA A 226;ASP A 222;ILE A 266;ILE A 278"," MG A 301 (-3.9A);None;None;None;None","1.15A","3ebzB-5jysA:undetectable","3ebzB-5jysA:14.62"],["3EBZ_B_017B201_2","5ldn","Human mastadenovirus C","HEXON PROTEIN,HEXON CAPSID","PF01065(Adeno_hexon);PF03678(Adeno_hexon_C)",5,"GLY A 220;ALA A 171;ILE A 215;GLY A 206;ILE A 205","None","0.81A","3ebzB-5ldnA:undetectable","3ebzB-5ldnA:9.06"],["3EBZ_B_017B201_2","5mpd","Saccharomyces cerevisiae","26S PROTEASOME REGULATORY SUBUNIT RPN2","PF01851(PC_rep);PF13646(HEAT_2)",5,"GLY N 698;ALA N 699;GLY N 704;ILE N 705;ILE N 678","None","0.78A","3ebzB-5mpdN:undetectable","3ebzB-5mpdN:7.72"],["3EBZ_B_017B201_2","5n7f","Homo sapiens","MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAIN-CONTAINING PROTEIN 1,ANNEXIN A2","no annotation",5,"GLY A 741;ALA A 740;ASP A 739;ASP A 736;ILE A 755"," CA A 905 (-4.7A);None;None;None;None","1.03A","3ebzB-5n7fA:undetectable","3ebzB-5n7fA:13.67"],["3EBZ_B_017B201_2","5nd1","Rosellinia necatrix quadrivirus 1","CAPSID PROTEIN","no annotation",5,"GLY B 438;ALA B 581;ASP A 872;VAL A 870;ILE B 689","None","1.09A","3ebzB-5nd1B:undetectable","3ebzB-5nd1B:19.00"],["3EBZ_B_017B201_2","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.27A","3ebzB-5t2zA:19.2","3ebzB-5t2zA:49.49"],["3EBZ_B_017B201_2","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","None","0.41A","3ebzB-5t2zA:19.2","3ebzB-5t2zA:49.49"],["3EBZ_B_017B201_2","5x1n","Sphingobium sp. SYK-6","VANILLATE\/3-O-METHYLGALLATE O-DEMETHYLASE","PF01571(GCV_T);PF08669(GCV_T_C)",5,"GLY A 168;ALA A 171;ASP A 173;GLY A 238;ILE A 230","None","1.14A","3ebzB-5x1nA:undetectable","3ebzB-5x1nA:16.71"],["3EBZ_B_017B201_2","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",5,"LEU A 308;ASP A 305;GLY A 272;GLY A 165;ILE A 152","None","1.01A","3ebzB-5xd6A:undetectable","3ebzB-5xd6A:22.55"],["3EBZ_B_017B201_2","5yeq","Sulfolobus acidocaldarius","KETOL-ACID REDUCTOISOMERASE (NADP(+))","no annotation",5,"LEU A 166;ALA A 149;ILE A 172;VAL A 137;GLY A 146","None","0.87A","3ebzB-5yeqA:undetectable","3ebzB-5yeqA:19.19"],["3EBZ_B_017B201_2","6cc2","Entamoeba histolytica","CELL DIVISION CONTROL PROTEIN 45 CDC45 PUTATIVE","no annotation",5,"GLY A 396;ALA A 360;ILE A 206;VAL A  33;GLY A 381","None","0.97A","3ebzB-6cc2A:undetectable","3ebzB-6cc2A:18.45"],["3EBZ_B_017B201_2","6dus","Salmonella enterica","TYPE III SECRETION SYSTEM EFFECTOR PROTEIN","no annotation",5,"LEU A  76;ALA A 227;ASP A 226;ASP A 228;ILE A  80","MPD A 506 ( 4.9A);UDP A 501 (-3.8A);UDP A 501 (-3.4A); MG A 503 ( 2.4A);MPD A 506 (-4.5A)","1.14A","3ebzB-6dusA:undetectable","3ebzB-6dusA:undetectable"],["3EBZ_B_017B201_2","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",7,"LEU A  28;ASP A  30;GLY A  32;ALA A  33;ASP A  34;ILE A  37;GLY A  58","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);3TL A 201 ( 4.8A);3TL A 201 (-3.4A)","0.45A","3ebzB-6fivA:15.8","3ebzB-6fivA:31.09"],["3EBZ_B_017B201_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  82","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-4.6A)","0.69A","3ebzB-6upjA:19.0","3ebzB-6upjA:98.99"],["3EBZ_B_017B201_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  32;GLY A  49","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A)","0.70A","3ebzB-6upjA:19.0","3ebzB-6upjA:98.99"],["3EBZ_B_017B201_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  32;VAL A  47;GLY A  49","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A)","0.66A","3ebzB-6upjA:19.0","3ebzB-6upjA:98.99"],["3EBZ_B_017B201_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ASP A  29;ASP A  30;GLY A  49;ILE A  50;ILE A  82","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);NIU A 100 (-4.6A)","0.80A","3ebzB-6upjA:19.0","3ebzB-6upjA:98.99"],["3EBZ_B_017B201_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ASP A  29;ILE A  32;GLY A  49;ILE A  50","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A)","0.81A","3ebzB-6upjA:19.0","3ebzB-6upjA:98.99"],["3EBZ_B_017B201_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ILE A  32;VAL A  47;GLY A  49;ILE A  50","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A)","0.77A","3ebzB-6upjA:19.0","3ebzB-6upjA:98.99"]]